President Donald Trump’s proposed budget blueprint calls for industry to double up on user fees to fully pay for FDA premarket approvals in exchange for administrative reforms aimed at speeding products to market. The fiscal 2018 skinny budget unveiled by the White House Thursday (March 16) said the increased fees would cover pre-market review costs in place of new budget authority, potentially throwing a wrench in congressional efforts to move forward on user fee reauthorization packages agreed to late last...